Giant Cell Arteritis Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals

The Giant Cell Arteritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Giant Cell Arteritis pipeline products will significantly revolutionize the Giant Cell Arteritis market dynamics.

DelveInsight's "Giant Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Giant Cell Arteritis, historical and forecasted epidemiology as well as the Giant Cell Arteritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Giant Cell Arteritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Giant Cell Arteritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Giant Cell Arteritis Market Insights https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Giant Cell Arteritis Overview
Giant Cell Arteritis (GCA), also called temporal arteritis, is a vasculitis that affects large and middle-sized blood vessels with predisposition to the involvement of cranial arteries derived from the carotid artery in individuals older than 50years of age. It is primarily a disease of cell-mediated immunity, which is thought to arise as a maladaptive response to endothelial injury. Actinic damage to the temporal artery from chronic sun exposure has been proposed as one source of the injury.

Some of the key facts of the Giant Cell Arteritis Market Report:
• The Giant Cell Arteritis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, the total number of prevalent cases of Giant Cell Arteritis was 435,887 cases in the year 2020 which are expected to grow during the study period, i.e. 2019-2032
• In the United States, the total number of prevalent cases of Giant Cell Arteritis was 2,44,438 cases in the year 2020 which are expected to grow during the study period, i.e.2019-2032
• As per the study by Crowson et al., United States population estimates, The overall age- and sex-adjusted prevalence rate of Giant Cell Arteritis was 204 (95% CI: 161-254) per 100,000 population aged ≥50 years
• Key Giant Cell Arteritis Companies: AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, and others
• Key Giant Cell Arteritis Therapies: Rinvoq (upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), and others

Get a Free sample for the Giant Cell Arteritis Market Report
https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key benefits of the Giant Cell Arteritis Market report:
1. Giant Cell Arteritis market report covers a descriptive overview and comprehensive insight of the Giant Cell Arteritis Epidemiology and Giant Cell Arteritis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Giant Cell Arteritis market report provides insights on the current and emerging therapies.
3. Giant Cell Arteritis market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Giant Cell Arteritis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Giant Cell Arteritis market.

Download the report to understand which factors are driving Giant Cell Arteritis epidemiology trends @ Giant Cell Arteritis Epidemiological Insights
https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Giant Cell Arteritis Market
The dynamics of the Giant Cell Arteritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

Giant Cell Arteritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Giant Cell Arteritis Epidemiology Segmentation:
The Giant Cell Arteritis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Giant Cell Arteritis
• Prevalent Cases of Giant Cell Arteritis by severity
• Gender-specific Prevalence of Giant Cell Arteritis
• Diagnosed Cases of Episodic and Chronic Giant Cell Arteritis

Giant Cell Arteritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Giant Cell Arteritis market or expected to get launched during the study period. The analysis covers Giant Cell Arteritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Giant Cell Arteritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Giant Cell Arteritis market share @ Giant Cell Arteritis market forecast
https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Giant Cell Arteritis Therapies and Key Companies
• Rinvoq (upadacitinib): AbbVie
• Cosentyx (secukinumab): Novartis Pharmaceuticals
• KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals

Giant Cell Arteritis Market Drivers
• Growing geriatric population
• Rise in prevalence of cardiovascular disorders

Scope of the Giant Cell Arteritis Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Giant Cell Arteritis Companies: AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, and others
• Key Giant Cell Arteritis Therapies: Rinvoq (upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), and others
• Giant Cell Arteritis Therapeutic Assessment: Giant Cell Arteritis current marketed and Giant Cell Arteritis emerging therapies
• Giant Cell Arteritis Market Dynamics: Giant Cell Arteritis market drivers and Giant Cell Arteritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Giant Cell Arteritis Unmet Needs, KOL's views, Analyst's views, Giant Cell Arteritis Market Access and Reimbursement

Giant Cell Arteritis Market Barriers
• Delay in Giant Cell Arteritis diagnosis
• Serious complications of Giant Cell Arteritis

Table of Contents
1. Giant Cell Arteritis Market Report Introduction
2. Executive Summary for Giant Cell Arteritis
3. SWOT analysis of Giant Cell Arteritis
4. Giant Cell Arteritis Patient Share (%) Overview at a Glance
5. Giant Cell Arteritis Market Overview at a Glance
6. Giant Cell Arteritis Disease Background and Overview
7. Giant Cell Arteritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Giant Cell Arteritis
9. Giant Cell Arteritis Current Treatment and Medical Practices
10. Giant Cell Arteritis Unmet Needs
11. Giant Cell Arteritis Emerging Therapies
12. Giant Cell Arteritis Market Outlook
13. Country-Wise Giant Cell Arteritis Market Analysis (2019-2032)
14. Giant Cell Arteritis Market Access and Reimbursement of Therapies
15. Giant Cell Arteritis Market Drivers
16. Giant Cell Arteritis Market Barriers
17. Giant Cell Arteritis Appendix
18. Giant Cell Arteritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about Giant Cell Arteritis treatment, visit @ Giant Cell Arteritis Medications
https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Giant Cell Arteritis Pipeline https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Giant Cell Arteritis Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Giant Cell Arteritis market. A detailed picture of the Giant Cell Arteritis pipeline landscape is provided, which includes the disease overview and Giant Cell Arteritis treatment guidelines.

Giant Cell Arteritis Epidemiology https://www.delveinsight.com/report-store/giant-cell-arteritis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Giant Cell Arteritis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Giant Cell Arteritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.